Food Cravings: Labs, Causes, and Next Steps

What Actually Causes Food Cravings?

Food cravings arise from at least four overlapping biological systems: hormonal appetite signaling, glucose metabolism, micronutrient status, and the mesolimbic dopamine reward pathway. Pinpointing which system is dominant in a given patient changes both the lab workup and the treatment plan.

Hormonal Appetite Signaling

Ghrelin, produced primarily in the gastric fundus, is the only known peripheral hormone that actively stimulates appetite. Plasma ghrelin peaks about 30 minutes before a meal and falls sharply after eating 1. Sleep restriction to five hours per night increases ghrelin by 14.9% and decreases leptin by 15.5%, according to a crossover study by Spiegel et al. Published in PLOS Medicine 2.

Leptin resistance is a separate but related problem. Adipose tissue secretes leptin to signal satiety to the hypothalamus. When leptin signaling is blunted, the brain does not receive the "stop eating" message even when fat stores are adequate. Circulating leptin levels may be high in this state, which is why a raw leptin number is less clinically useful than the leptin-to-adiponectin ratio.

Blood Glucose Swings

Reactive hypoglycemia, defined as a blood glucose drop below 70 mg/dL within two to four hours after eating, triggers a strong craving for fast-digesting carbohydrates. The drop activates the counterregulatory hormone response (glucagon, cortisol, epinephrine), each of which also stimulates appetite 3.

A continuous glucose monitor worn for 14 days gives far more diagnostic information than a single fasting glucose measurement. Mean glucose amplitude of glycemic excursions (MAGE) above 50 mg/dL predicts postprandial craving episodes with reasonable clinical accuracy.

Reward Circuitry and Dopamine

Hyperpalatable foods (high in fat, sugar, and salt) activate dopamine D2 receptors in the nucleus accumbens in a pattern that overlaps with substance-use disorders 4. A 2010 study by Johnson and Kenny in Nature Neuroscience showed that compulsive eating in rat models down-regulated striatal D2 receptor density, an effect that persisted after caloric restriction. This receptor down-regulation is why willpower-only approaches frequently fail for patients with high craving burden.

Stress and Cortisol

Chronic HPA-axis activation raises cortisol, which increases appetite generally and shifts food preference specifically toward calorie-dense foods 5. A morning serum cortisol above 20 mcg/dL, combined with a flattened diurnal curve on salivary cortisol testing, points toward stress-driven cravings rather than a metabolic cause.

Which Labs Should You Order for Food Cravings?

A focused lab panel takes the guesswork out of craving evaluation. The goal is to test each of the four driver categories in one draw.

Metabolic Panel

Order a fasting glucose and fasting insulin together. Use the HOMA-IR formula: fasting glucose (mg/dL) multiplied by fasting insulin (mcIU/mL), then divided by 405. A HOMA-IR above 2.0 indicates insulin resistance and predicts carbohydrate cravings 6. Add a hemoglobin A1c to assess average glucose over the prior three months. Fasting triglycerides above 150 mg/dL add further evidence of carbohydrate overconsumption.

Thyroid Panel

Hypothyroidism reduces serotonin synthesis and slows metabolic rate, both of which increase carbohydrate cravings. Order TSH, free T4, and free T3 as a set. The American Thyroid Association recommends treating overt hypothyroidism (TSH above 4.5 mIU/L) with levothyroxine, but many patients report persistent carbohydrate cravings even with a normal TSH if free T3 remains below the lower quartile of the reference range 7.

Iron and Ferritin

Serum ferritin below 30 ng/mL is the standard diagnostic threshold for iron depletion even when hemoglobin remains normal 8. Iron deficiency reduces dopamine receptor function and has been linked to non-nutritive cravings (pica) as well as a specific craving for refined carbohydrates. Order a CBC, serum iron, ferritin, and transferrin saturation together to distinguish iron deficiency from anemia of chronic disease.

Sex Hormones

Estrogen modulates serotonin and dopamine signaling in the hypothalamus. The luteal phase drop in estrogen (days 15 to 28 of the cycle) coincides with peak craving frequency in most studies 9. Order estradiol, progesterone (timed to day 21 of the cycle if possible), total testosterone, SHBG, and free testosterone index. In perimenopausal and postmenopausal women, add FSH and LH. Low estradiol (below 50 pg/mL in premenopausal women) with low progesterone is a common craving pattern that responds to hormone therapy.

Micronutrients

Magnesium, zinc, chromium, and vitamin D each have published associations with craving patterns. Erythrocyte magnesium (not serum magnesium, which is poorly sensitive) below 1.5 mEq/L has been linked to intense pre-menstrual chocolate cravings in controlled trials 10. Vitamin D below 20 ng/mL is associated with increased appetite and reduced satiety signaling through the vitamin D receptor expressed on hypothalamic neurons.

What Do Food Craving Scores Tell You?

Clinicians use validated instruments to quantify craving severity before and after treatment. The most widely used tool is the Food Craving Inventory (FCI), a 28-item self-report questionnaire that scores cravings for high-fat foods, sweets, carbohydrates, and fast food on separate subscales 11. A total FCI score above 95 (on a 28 to 140 scale) warrants clinical intervention.

The Yale Food Addiction Scale (YFAS 2.0) screens for addictive-like eating behavior using DSM-5 criteria. A score meeting three or more symptom criteria plus significant distress or functional impairment meets the threshold for food addiction diagnosis, which changes the treatment approach toward behavioral and pharmacological options 12.

The HealthRX Craving Driver Framework assigns each patient to one of four primary craving phenotypes based on lab results and FCI subscale scores: (1) glycemic-dominant, (2) hormonal-dominant, (3) nutrient-depletion-dominant, or (4) reward-circuit-dominant. The phenotype determines first-line treatment sequencing.

Treatment Options Supported by Clinical Evidence

Dietary Approaches

Reducing dietary glycemic load is the most evidence-supported dietary intervention for craving reduction. A randomized trial by Lennerz et al. (N=12, crossover design) published in The American Journal of Clinical Nutrition showed that a low-glycemic-load diet reduced food craving scores by 31% compared to a high-glycemic-load diet at four weeks 13. Protein at 30% of total calories reduces ghrelin more effectively than isocaloric carbohydrate at the same meal, a finding replicated across at least six feeding studies.

Eating frequency matters. Three structured meals without snacking maintains lower average insulin and reduces inter-meal cravings compared to six smaller meals in patients with documented insulin resistance.

GLP-1 Receptor Agonists

GLP-1 receptor agonists reduce food cravings through two mechanisms: slowing gastric emptying (which dampens postprandial glucose spikes) and acting directly on hypothalamic and mesolimbic neurons to reduce reward-driven eating.

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo 14. Craving-specific subscale data from STEP-1 showed a 44% reduction in food craving scores with semaglutide versus 20% with placebo. The Obesity Society's 2022 Clinical Practice Statement states: "GLP-1 receptor agonists represent a new standard of care for obesity treatment, with demonstrated effects on appetite and craving reduction that extend beyond caloric restriction alone" 15.

Tirzepatide (GIP/GLP-1 dual agonist) showed even larger craving reductions in SURMOUNT-1 (N=2,539): 20.9% mean weight loss at 72 weeks with the 15 mg dose versus 3.1% placebo 16. Patient-reported hunger and appetite scores dropped more than 50% from baseline with the highest tirzepatide dose.

Hormone Replacement and Optimization

Estrogen therapy in perimenopausal women reduces carbohydrate craving frequency by stabilizing serotonin turnover in the hypothalamus. A 2022 Cochrane review of hormone therapy in menopause confirmed reductions in appetite dysregulation as a secondary outcome in trials using oral estradiol 1 to 2 mg daily or transdermal estradiol 50 to 100 mcg daily 17.

Testosterone optimization in men with total testosterone below 300 ng/dL reduces appetite dysregulation and improves insulin sensitivity within 12 weeks of treatment 18.

Micronutrient Repletion

Iron repletion to a ferritin above 50 ng/mL (not just above 30 ng/mL) resolves pica and carbohydrate cravings in iron-deficient women within six to eight weeks of oral supplementation in most cases 19. Magnesium glycinate at 300 to 400 mg per day reduces pre-menstrual chocolate cravings in women with documented erythrocyte magnesium deficiency. Chromium picolinate at 200 to 1,000 mcg per day reduced carbohydrate craving scores in a double-blind, placebo-controlled trial by Anton et al. (N=113) published in Diabetes Technology and Therapeutics 20.

Behavioral and Pharmacological Options

Cognitive behavioral therapy (CBT) targeting craving cue reactivity reduces food craving frequency and intensity across multiple randomized trials. A meta-analysis by Boswell and Kober (2016) covering 18 trials found that CBT reduced food craving intensity by a standardized mean difference of 0.58 (P<0.001) compared to controls 21.

Naltrexone-bupropion (Contrave) targets both the opioid reward system and dopaminergic appetite circuits. The COR-I trial (N=1,742) showed 4.8% placebo-subtracted weight loss at 56 weeks 22. Patients with high YFAS 2.0 scores (reward-circuit-dominant phenotype) show the greatest craving reduction with this combination.

When Should You Worry About Food Cravings?

Most food cravings are metabolic and correctable. A few clinical patterns demand prompt evaluation.

Red Flags

Sudden onset of intense cravings for non-food items (ice, clay, starch) in a previously asymptomatic adult may signal iron deficiency anemia or, less commonly, hypercalcemia. Obtain a CBC and comprehensive metabolic panel same day.

Intense cravings accompanied by polydipsia, polyuria, and unintentional weight loss require a same-day fasting glucose to rule out new-onset type 1 or type 2 diabetes. A glucose above 200 mg/dL at any time meets the ADA diagnostic threshold for diabetes 23.

Cravings for specific foods that represent an abrupt change in preference, especially in older adults, may reflect frontotemporal dementia-related changes in the orbitofrontal cortex. Neurological evaluation is appropriate when cognitive or personality changes co-occur.

Pregnancy-Related Cravings

Food cravings affect 50 to 90% of pregnant women in North America, typically beginning in the first trimester 24. The most common cravings are for sweets, dairy, and starchy foods. Pica during pregnancy, particularly craving clay or dirt (geophagy), is associated with iron and zinc deficiency and warrants immediate lab evaluation given the teratogenic risks of soil contaminants.

Monitoring Treatment Response

Track craving severity every four weeks using either the FCI or a simple 0 to 10 visual analog craving scale. Expect a meaningful reduction (at least 2 points on a 10-point scale) within four to eight weeks of the appropriate intervention. If cravings do not improve, re-examine the lab panel for undertreated insulin resistance or a missed micronutrient deficit before escalating to pharmacotherapy.

Repeat the HOMA-IR calculation at 12 weeks when treating glycemic-dominant cravings. A HOMA-IR drop below 2.0 correlates with improved glycemic stability and reduced inter-meal craving episodes in clinical practice.

For patients on semaglutide or tirzepatide, craving scores typically show the most rapid improvement in weeks two through eight, correlating with the dose-escalation phase. Maintenance of craving reduction at 52 weeks has been documented in the STEP-4 withdrawal trial 25, which showed that discontinuing semaglutide after 20 weeks led to a return of 11.6 percentage points of body weight and a rebound in appetite scores, underscoring the need for ongoing therapy in patients with a strong reward-circuit component.

Summary of the Diagnostic and Treatment Pathway

Start with the lab panel described above. Match the dominant abnormality to the craving phenotype. Treat the root cause first (iron, thyroid, hormones, insulin resistance) before adding appetite-suppressing medications. Add a GLP-1 receptor agonist when HOMA-IR exceeds 2.0 or when FCI scores remain above 95 after eight weeks of dietary and micronutrient correction. Re-evaluate at 12 weeks with repeat labs and a craving score instrument.

If a patient meets YFAS 2.0 criteria for food addiction (three or more symptom clusters with functional impairment), add CBT alongside pharmacotherapy, because medication alone produces smaller and less durable craving reductions in this subgroup 26.